JP2019524111A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524111A5
JP2019524111A5 JP2019503341A JP2019503341A JP2019524111A5 JP 2019524111 A5 JP2019524111 A5 JP 2019524111A5 JP 2019503341 A JP2019503341 A JP 2019503341A JP 2019503341 A JP2019503341 A JP 2019503341A JP 2019524111 A5 JP2019524111 A5 JP 2019524111A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
chain variable
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019503341A
Other languages
English (en)
Japanese (ja)
Other versions
JP7082967B2 (ja
JP2019524111A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/043504 external-priority patent/WO2018018039A2/en
Publication of JP2019524111A publication Critical patent/JP2019524111A/ja
Publication of JP2019524111A5 publication Critical patent/JP2019524111A5/ja
Application granted granted Critical
Publication of JP7082967B2 publication Critical patent/JP7082967B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019503341A 2016-07-22 2017-07-24 グルココルチコイド誘導性腫瘍壊死因子受容体(gitr)抗体及びその使用方法 Active JP7082967B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662365712P 2016-07-22 2016-07-22
US62/365,712 2016-07-22
US201662375634P 2016-08-16 2016-08-16
US62/375,634 2016-08-16
PCT/US2017/043504 WO2018018039A2 (en) 2016-07-22 2017-07-24 Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2019524111A JP2019524111A (ja) 2019-09-05
JP2019524111A5 true JP2019524111A5 (https=) 2020-09-03
JP7082967B2 JP7082967B2 (ja) 2022-06-09

Family

ID=59501631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503341A Active JP7082967B2 (ja) 2016-07-22 2017-07-24 グルココルチコイド誘導性腫瘍壊死因子受容体(gitr)抗体及びその使用方法

Country Status (13)

Country Link
US (2) US11046777B2 (https=)
EP (1) EP3487884A2 (https=)
JP (1) JP7082967B2 (https=)
KR (1) KR102534568B1 (https=)
CN (2) CN116082506A (https=)
AU (2) AU2017300788B2 (https=)
BR (1) BR112019001262A2 (https=)
CA (1) CA3031194A1 (https=)
IL (2) IL296127B2 (https=)
MX (2) MX2019000963A (https=)
RU (1) RU2019104896A (https=)
SG (1) SG11201900500TA (https=)
WO (1) WO2018018039A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210070860A1 (en) * 2018-03-21 2021-03-11 Dana-Farber Cancer Institute, Inc. Fc variant compositions and methods of use thereof
MX2020010653A (es) * 2018-04-09 2020-10-28 Origincell Therapeutics Co Ltd Anticuerpo anti-muerte programada-ligando 1 y su uso.
MX2022012076A (es) * 2020-05-21 2022-10-13 Zydus Lifesciences Ltd Variante del fc y preparacion de la misma.
EP4225804A4 (en) * 2020-10-09 2025-07-02 Hospital For Sick Children POLYPEPTIDES TARGETING SARS-CoV-2, COMPOSITIONS AND RELATED METHODS
CN119751680A (zh) * 2021-12-06 2025-04-04 重庆精准生物技术有限公司 靶向cd22的抗原结合片段和单链抗体及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0666923A1 (en) 1991-09-05 1995-08-16 The University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20090130123A1 (en) * 2004-06-15 2009-05-21 Erol Fikrig Antibodies to west nile virus polypeptides
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
KR101790802B1 (ko) * 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-gitr 항체
WO2013039954A1 (en) * 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) * 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
SI3148579T1 (sl) * 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
PE20170441A1 (es) 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
RU2017115315A (ru) * 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
MA41044A (fr) * 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016073906A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
CN120795163A (zh) * 2016-10-14 2025-10-17 丹娜法伯癌症研究所公司 模块化四聚体双特异性抗体平台
EP3576793A4 (en) * 2017-02-06 2021-03-31 Dana Farber Cancer Institute, Inc. COMPOSITIONS AND PROCEDURES FOR ENHANCING ANTIBODY-MEDIATED RECEPTOR SIGNALING

Similar Documents

Publication Publication Date Title
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2017531427A5 (https=)
JP2015535691A5 (https=)
JP2019524111A5 (https=)
JP2020103301A5 (https=)
JP2022159548A5 (https=)
JP2020504076A5 (https=)
JP2017114866A5 (https=)
JP2018121657A5 (https=)
JP2020127426A5 (https=)
JP2020525032A5 (https=)
JP2018523493A5 (https=)
HRP20192098T1 (hr) Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene
JP2016505635A5 (https=)
JP2017506067A5 (https=)
JP2013227339A5 (https=)
JP2020510422A5 (https=)
JP2019507762A5 (https=)
JP2017149720A5 (https=)
JP2019523221A5 (https=)
JP2013502913A5 (https=)
JP2019525771A5 (https=)
JP2019513777A5 (https=)
JP2012519492A5 (https=)
JP2014111644A5 (https=)